Skip to main content
Premium Trial:

Request an Annual Quote

MorphoSys' Q2 Revenue Grows 42 Percent Though Profit Turns to Loss

NEW YORK (GenomeWeb News) – MorphoSys today reported a net loss for the second quarter although revenue grew 47 percent.
 
Receipts for the three months ended June 30 increased to $11.7 million from $7.9 million year over year.
 
R&D costs increased 24 percent to $4 million from $3 million from the comparable quarter a year ago.
 
MorphoSys reported a net loss of 400,000 for the quarter, compared to a net profit of $1.3 million during the comparable period last year.
 
As reported yesterday in GenomeWeb News, MorphoSys raised its revenue guidance for 2006 to $52 million from $50 million.
 
MorphoSys's said it had around $1.6 million in cash and cash equivalents as of June 30.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.